VivoSeq
Other

Netherton Syndrome

9

Pipeline Programs↗

5

Active Trials↗

5

Companies Involved↗

Netherton syndrome is an early-stage landscape with 9 programs across 5 companies. The most active players are Novartis, Boehringer Ingelheim, Daiichi Sankyo. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

38/100

Pipeline Velocity

6/100

Mech. Concentration

25/100

Completion Rate

57/100

Attrition Rate

23/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

1 program

Phase 1Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 2Daiichi Sankyo logo

Daiichi Sankyo

1 program

Phase 2S

Sixera Pharma

1 program

Phase 2Q

Quoin Pharmaceuticals

3 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

75%

Small molecule

9 of 12 classified programs — the dominant modality here.

25%ALL OTHERSMonoclonal antibody325%

Small molecule leads; the ring shows all 12 classified programs, each share of the total. Modality classified for 100% of 16 pipeline programs.

Analysis

Trial Status

13

clinical trials

Completed4 · 31%
Recruiting4 · 31%
Terminated3 · 23%
Unknown status1 · 8%
Active, not recruiting1 · 8%

Clinical Trials

Trial Activity

13 trials

Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome
Recruiting·QQuoin Pharmaceuticals·Phase 2/3·NCT05789056·20 enrolled
Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome
Recruiting·AAzitra Inc.·Phase 1·NCT06137157·12 enrolled
Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
Recruiting·QQuoin Pharmaceuticals·Phase 2/3·NCT06953466·8 enrolled
Study of Skin and Gut Microbiome in a Skin Condition Involving Skin Barrier Impairment and Allergic Symptoms: Netherton Syndrome
Recruiting·AAssistance Publique - Hôpitaux de Paris·N/A·NCT07280091·30 enrolled
Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome
Active, not recruiting·QQuoin Pharmaceuticals·Phase 2/3·NCT05521438·30 enrolled
Clinical Trial Using Humira in Netherton Syndrome
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT02113904·11 enrolled
A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome
Completed·Novartis logoNovartis·Phase 1·NCT01428297·12 enrolled
A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton Syndrome
Completed·SSixera Pharma·Phase 1/2·NCT05211830·9 enrolled
Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome
Completed·—·Phase 1/2·NCT00208026·3 enrolled
A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome
Terminated·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 2/3·NCT05856526·43 enrolled
A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome
Terminated·Daiichi Sankyo logoDaiichi Sankyo·Phase 1/2·NCT05979831·9 enrolled
Non-interventional Study of Patients With Netherton Syndrome to Characterise the Natural History of Disease
Terminated·Boehringer Ingelheim logoBoehringer Ingelheim·N/A·NCT05902663·4 enrolled
A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome
Unknown status·UUniversity Hospital, Toulouse·Phase 2/3·NCT04244006·24 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)